MX2023004998A - Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. - Google Patents
Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.Info
- Publication number
- MX2023004998A MX2023004998A MX2023004998A MX2023004998A MX2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- treating cancers
- quinazoline derivatives
- substituted quinazoline
- alkyne substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108645P | 2020-11-02 | 2020-11-02 | |
| US202163166045P | 2021-03-25 | 2021-03-25 | |
| US202163190067P | 2021-05-18 | 2021-05-18 | |
| US202163218717P | 2021-07-06 | 2021-07-06 | |
| US202163237782P | 2021-08-27 | 2021-08-27 | |
| US202163244540P | 2021-09-15 | 2021-09-15 | |
| PCT/US2021/057724 WO2022094464A1 (en) | 2020-11-02 | 2021-11-02 | Method of treating cancers with alkyne substituted quinazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004998A true MX2023004998A (es) | 2023-05-12 |
Family
ID=78819639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004998A MX2023004998A (es) | 2020-11-02 | 2021-11-02 | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240075042A1 (https=) |
| EP (1) | EP4236954A1 (https=) |
| JP (1) | JP2023548055A (https=) |
| KR (1) | KR20230093429A (https=) |
| AU (1) | AU2021368798A1 (https=) |
| CA (1) | CA3195473A1 (https=) |
| IL (1) | IL302329A (https=) |
| MX (1) | MX2023004998A (https=) |
| TW (1) | TWI910256B (https=) |
| WO (1) | WO2022094464A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CA3231697A1 (en) * | 2021-09-21 | 2023-03-30 | Black Diamond Therapeutics, Inc. | Polymorphs as erbb inhibitors |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025128831A1 (en) * | 2023-12-13 | 2025-06-19 | Black Diamond Therapeutics, Inc. | Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122058A2 (en) * | 2011-03-04 | 2012-09-13 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
| US20180193274A1 (en) * | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
| JP2022502495A (ja) * | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用 |
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
-
2021
- 2021-11-02 US US18/034,749 patent/US20240075042A1/en active Pending
- 2021-11-02 MX MX2023004998A patent/MX2023004998A/es unknown
- 2021-11-02 KR KR1020237013278A patent/KR20230093429A/ko active Pending
- 2021-11-02 EP EP21816235.2A patent/EP4236954A1/en active Pending
- 2021-11-02 IL IL302329A patent/IL302329A/en unknown
- 2021-11-02 JP JP2023524708A patent/JP2023548055A/ja active Pending
- 2021-11-02 AU AU2021368798A patent/AU2021368798A1/en active Pending
- 2021-11-02 WO PCT/US2021/057724 patent/WO2022094464A1/en not_active Ceased
- 2021-11-02 CA CA3195473A patent/CA3195473A1/en active Pending
- 2021-11-02 TW TW110140833A patent/TWI910256B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI910256B (zh) | 2026-01-01 |
| IL302329A (en) | 2023-06-01 |
| AU2021368798A9 (en) | 2023-07-06 |
| KR20230093429A (ko) | 2023-06-27 |
| EP4236954A1 (en) | 2023-09-06 |
| WO2022094464A1 (en) | 2022-05-05 |
| US20240075042A1 (en) | 2024-03-07 |
| CA3195473A1 (en) | 2022-05-05 |
| JP2023548055A (ja) | 2023-11-15 |
| AU2021368798A1 (en) | 2023-05-18 |
| TW202235083A (zh) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004998A (es) | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| CL2022002515A1 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| MX2021007833A (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| WO2019191470A8 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2025002218A (es) | Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3 | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| MX2023004937A (es) | Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas. | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| DOP2025000212A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| CL2025002792A1 (es) | Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores | |
| CL2024001524A1 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| MX2025005365A (es) | Compuestos triciclicos | |
| AR133935A1 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| WO2022183034A8 (en) | Nrf2 inhibitors and uses thereof |